NCT04853069 - Oestrogen Treatment for COVID-19 Symptoms | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

March 31, 2022

Conditions

COVID-19

Interventions

DRUG

Transdermal estradiol gel

Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.

Trial Locations (1)

PO Box 3050

Hamad Medical Corporation, Doha